Compare VKTX & MIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VKTX | MIR |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | 2014 | 2020 |
| Metric | VKTX | MIR |
|---|---|---|
| Price | $28.77 | $15.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $95.86 | $27.25 |
| AVG Volume (30 Days) | 1.8M | ★ 3.3M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $23.95 |
| Revenue Next Year | N/A | $7.32 |
| P/E Ratio | ★ N/A | $812.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.52 | $14.11 |
| 52 Week High | $43.15 | $30.28 |
| Indicator | VKTX | MIR |
|---|---|---|
| Relative Strength Index (RSI) | 30.44 | 51.98 |
| Support Level | $26.47 | $15.60 |
| Resistance Level | $35.36 | $16.08 |
| Average True Range (ATR) | 1.35 | 0.67 |
| MACD | -0.46 | 0.04 |
| Stochastic Oscillator | 6.26 | 57.37 |
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.